3rd Quarter - Report
SPLITOAK STRATEGIES LLC for ALNYLAM PHARMACEUTICALS, INC.
Income
$60,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; U.S. Competitiveness
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction |
| AMY JENSEN | 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs |
Health Issues HCR
FDA modernization
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | Sarah: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction |
| AMY JENSEN | Amy: 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.